Market News
4 min read | Updated on May 27, 2025, 12:56 IST
SUMMARY
The SENSEX recovered as much as 1,149 points from day's lowest level and NIFTY50 touched high of 25,062.90 after hitting low of 24,737.
Stock list
Shares of Aurobindo Pharma rose 2.36% to hit an intraday high of ₹1,207. | Image: Shutterstock
The Indian equity benchmarks staged a strong recovery in the late morning deals on Tuesday, May 27, owing to buying interest in index heavyweights such as HDFC Bank, State Bank of India, Bharti Airtel, Larsen & Toubro, IndusInd Bank, Sun Pharma and Adani Ports. The SENSEX recovered as much as 1,149 points from the day's lowest level, and the NIFTY50 touched a high of 25,062.90 after hitting a low of 24,737.
The sale includes an initial tranche of 34.61 crore equity shares, representing a 7.39% stake, with an option to offload an additional 35.69 crore shares (7.62%) in case of oversubscription.
The OFS for non-retail investors will open on Tuesday, May 27, and will be available to both retail and non-retail investors from May 28. The floor price has been set at ₹38 per share, the company said in an exchange filing.
According to NSE data, the ₹144.89-crore initial share sale received bids for 54,88,84,443 shares against 36,89,457 shares on offer. The initial public offering (IPO) of Borana Weaves got subscribed a huge 148.77 times on the closing day of bidding on Thursday, May 22.
The shares of the company were last seen at ₹896.25 apiece, rising 4.04% on the National Stock Exchange (NSE).
The floor price for the PG Electroplast block deal is set at ₹740 per share, a 4% discount to Monday's closing. The sellers include Anurag Gupta, Vishal Gupta, Vikas Gupta, Pranav Gupta, Aditya Gupta, Raghav Gupta, Vatsal Gupta, Vrinda Gupta and Shraddha Gupta, the report added.
Its revenue from operations, however, rose 16% to ₹1,930 crore from ₹1,667 crore in the year-ago period.
Its total revenue from operations stood at ₹8,382 crore for the fourth quarter compared to ₹7,580 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing.
About The Author